Legal & General Group
FDMT icon

Legal & General Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Legal & General Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.2K Buy
4,448
+753
+20% +$7.34K ﹤0.01% 2721
2026
Q1 		$34.4K Hold
3,695
– – ﹤0.01% 2779
2025
Q4 		$27.7K Hold
3,695
– – ﹤0.01% 2904
2025
Q3 		$32.1K Hold
3,695
– – ﹤0.01% 2860
2025
Q2 		$13.7K Sell
3,695
-8,919
-71% -$31.4K ﹤0.01% 3164
2025
Q1 		$40.7K Sell
12,614
-21,666
-63% -$102K ﹤0.01% 2754
2024
Q4 		$191K Buy
34,280
+1,906
+6% +$15K ﹤0.01% 2667
2024
Q3 		$350K Buy
32,374
+2,736
+9% +$45.4K ﹤0.01% 2572
2024
Q2 		$622K Buy
29,638
+4,451
+18% +$112K ﹤0.01% 2346
2024
Q1 		$802K Buy
25,187
+638
+3% +$16.3K ﹤0.01% 2265
2023
Q4 		$497K Buy
24,549
+138
+0.6% +$1.82K ﹤0.01% 2450
2023
Q3 		$311K Buy
24,411
+235
+1% +$3.93K ﹤0.01% 2619
2023
Q2 		$437K Buy
24,176
+17,108
+242% +$315K ﹤0.01% 2510
2023
Q1 		$121K Buy
7,068
+4,222
+148% +$82.1K ﹤0.01% 2739
2022
Q4 		$63.2K Sell
2,846
-6,541
-70% -$101K ﹤0.01% 2907
2022
Q3 		$75K Hold
9,387
– – ﹤0.01% 2892
2022
Q2 		$66K Buy
9,387
+1,147
+14% +$11.2K ﹤0.01% 2948
2022
Q1 		$125K Hold
8,240
– – ﹤0.01% 2810
2021
Q4 		$181K Buy
8,240
+2,735
+50% +$67K ﹤0.01% 2763
2021
Q3 		$149K Buy
5,505
+4,691
+576% +$134K ﹤0.01% 2760
2021
Q2 		$20K Buy
814
+22
+3% +$673 ﹤0.01% 3290
2021
Q1 		$34K Buy
+792
New +$35.1K ﹤0.01% 2947

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Legal & General Group's FDMT Position: Q2 2026 in Review

Legal & General Group increased its 4D Molecular Therapeutics (FDMT) stake by 20% in Q2 2026, buying an estimated $7.34K and bringing the position to 4,448 shares worth $59.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Legal & General Group first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $802K in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Legal & General Group held 4,448 shares of 4D Molecular Therapeutics worth $59.2K as of Q2 2026.
  • Legal & General Group bought 753 4D Molecular Therapeutics shares in Q2 2026, an estimated $7.34K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2721 holding.
  • Legal & General Group first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Legal & General Group's 4D Molecular Therapeutics position peaked at $802K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.